Back grey_arrow_rt.gif
 
Recent articles on HIV.
 
null.gif
 
 
  1. Tibotec Launches Email/Text Message Adherence Program
     
  2. GSK Response Letters to Abacavir Article in the The Independent - (05/15/08)
     
  3. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. - (05/10/08)
     
  4. Comparative Efficacy between therapies for bone disease: What We Know, What We Need to Know, and How We Can Get There EDITORIAL - (05/10/08)
     
  5. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. "Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians" - (05/10/08)
     
  6. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? [RESEARCH LETTERS] - (05/07/08)
     
  7. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
     
  8. Bone health & Antiepileptic Drugs - (05/02/08)
     
  9. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy - (05/02/08)
     
  10. Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction - (05/02/08)
     
  11. EASL: NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease - (05/02/08)
     
  12. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
     
  13. Diabetes drugs (glitazones) double fracture risk: Swiss study - (05/01/08)
     
  14. EASL: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY - (04/25/08)
     
  15. EASL: NEW HCV DRUGS at EASL Apr 23-27, 2008 Milan - (04/23/08)
     
  16. EASL: Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/23/08)
     
  17. EASL: HCV Drug Resistance - (04/23/08)
     
  18. The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy - Written by Jennifer J. Kiser, Pharm.D. - (04/22/08)
     
  19. 9th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Jennifer J. Kiser, Pharm.D. and Courtney V. Fletcher, Pharm.D. (04/22/08)
     
  20. Insulin Resistance Confounds Heart Disease Studies in HIV: Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy - (04/22/08)
     
  21. CD4 Count & Viral Load Predict non-AIDS & AIDS diseases: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection - (04/22/08)
     
  22. Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study - (04/21/08)
     
  23. Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up - (04/21/08)
     
  24. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  25. CROI: Women, Younger Age & Black Race Associated with Shorter Time to Viral Failure: Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection - (04/21/08)
     
  26. DASH Diet Reduces Heart Disease Risk by 24% - (04/18/08)
     
  27. The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen. - (04/18/08)
     
  28. Gut (liver), inflammation and osteoporosis: basic and clinical concepts - (04/16/08)
     
  29. SCHERING-PLOUGH INITIATES PHASE II STUDY WITH VICRIVIROC IN TREATMENT-NAIVE HIV-INFECTED PATIENTS: Novel Nucleoside-Sparing Regimen Designed to Avoid Risk of Toxicity Associated with Nucleoside Class of HIV Drugs - (04/15/08)
     
  30. TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2 - (04/15/08)
     
  31. 9th Int Wrkshp Pharm HIV: Safety, Tolerability and Activity of KP-1461 a Novel Viral Mutagen in HIV Infected Adults - (04/15/08)
     
  32. Walking and primary prevention: a meta-analysis of prospective cohort studies - (04/14/08)
     
  33. Maximal oxygen intake and independence in old age: aorobic exercise adds 12 years of life - (04/14/08)
     
  34. 9th Int Wrkshp Pharm HIV: Does HCV or HBV co-infection influence saquinavir exposure in HIV-infected patients without liver function impairment? - (04/14/08)
     
  35. 9th Int Wrkshp Pharm HIV: The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI - (04/14/08)
     
  36. 9th Int Wrkshp Pharm HIV: Pharmacokinetic/Pharmacodynamic (PK/PD) analyses for Raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients - (04/14/08)
     
  37. 9th Int Wrkshp Pharm HIV: The effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral (ARV)-naive HIV-1-infected patients (04/10/08)
     
  38. 9th Int Wrkshp Pharm HIV: Is Twice-Daily Unboosted Atazanavir 200 mg Worth a Harder Look? (04/10/08)
     
  39. 9th Int Wrkshp Pharm HIV: Black Race and Drug Interactions Affect Nonnucleoside Levels in TDM Analysis (04/10/08)
     
  40. Survey highlights lack of sleep: higher insulin levels; heart disease; inflammation; mental/cognitive disorders - (04/10/08)
     
  41. Sleep and HIV illness. - (04/10/08)
     
  42. Insomnia in HIV Infection: A Systematic Review of Prevalence, Correlates, and Management - (04/10/08)
     
  43. High Prevalence of Insomnia in an Outpatient Population With HIV Infection - (04/10/08)
     
  44. 9th Int Wrkshp Pharm HIV: CASTLE Study: Pharmacokinetics and Inhibitory Quotient of Atazanavir/ritonavir 300/100 mg Once Daily Compared to Lopinavir/ritonavir 400/100 mg Twice Daily, Each in Combination with Fixed Dose Tenofovir-Emtricitabine Once Daily, Are Supportive of 48 Week Efficacy and Safety in HIV-1 Infected, Treatment-Naive Subjects (04/10/08)
     
  45. 9th Int Wrkshp Pharm HIV: Single-Dose Pharmacokinetics of Enteric-Coated Didanosine in Subjects with Hepatic Impairment Compared to Healthy Adult Subjects (04/10/08)
     
  46. 9th Int Wrkshp Pharm HIV: Effect of Atazanavir with and without Ritonavir on the Pharmacokinetics of the CYP2C8 Probe Rosiglitazone in Healthy Subjects (04/10/08)
     
  47. 9th Int Wrkshp Pharm HIV: A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients (04/10/08)
     
  48. 9th Int Wrkshp Pharm HIV: The pharmacokinetic (PK) profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours (04/10/08)
     
  49. 9th Int Wrkshp Pharm HIV: Raltegravir Levels Down With Tipranavir and Up With Atazanavir (04/10/08)
     
  50. 9th Int Wrkshp Pharm HIV: Once-Daily Darunavir/Ritonavir Keeps Levels High in Healthy Volunteers - written by Mark Mascolini (04/09/08)
     
  51. 9th Int Wrkshp Pharm HIV: Vicriviroc Troughs Correlate With Response in VICTOR-E1 Salvage Study - written by Mark Mascolini (04/09/08)
     
  52. 9th Int Wrkshp Pharm HIV: Raltegravir Levels May Drop With Lopinavir/Ritonavir - written by Mark Mascolini (04/09/08)
     
  53. 9th Int Wrkshp Pharm HIV: Pharmacokinetic Profile of Darunavir (DRV) Co-Administered With Low-Dose Ritonavir (DRV/r) in Treatment-Experienced Women and Men With HIV Infection: 4-Week Analysis in a Substudy of the GRACE (Gender, Race, and Clinical Experience) Study (04/09/08)
     
  54. 9th Int Wrkshp Pharm HIV: Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects; tenofovir and HCV affect levels (04/09/08)
     
  55. 9th Int Wrkshp Pharm HIV: Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (04/09/08)
     
  56. 9th Int Wrkshp Pharm HIV: Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir in HIV-1-infected patients: results of a randomized, controlled, Phase III study (ARTEMIS) (04/09/08)
     
  57. 9th Int Wrkshp Pharm HIV: Darunavir and Ritonavir Levels in Black and Hispanic Women - Written by Mark Mascolini (04/08/08)
     
  58. 9th Int Wrkshp Pharm HIV: Higher Efavirenz Levels--But No More Toxicity--in Nonwhites vs Whites: EuroSIDA - Written by Mark Mascolini (04/08/08)
     
  59. 9th Int Wrkshp Pharm HIV: Etravirine Levels - Written by Mark Mascolini (04/08/08)
     
  60. 9th Int Wrkshp Pharm HIV: Tenofovir, Hepatitis, and Weight Moderately Affect Etravirine Levels - Written by Mark Mascolini (04/08/08)
     
  61. New Abbott Kaletra (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe - (04/08/08)
     
  62. DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir - April 4, 2008 - (04/08/08)
     
  63. HPV in Heterosexuals. Prevalence and factors associated with anal lesions mediated by human papillomavirus in men with HIV/AIDS - (04/08/08)
     
  64. Osteoporosis in Men - (04/07/08)
     
  65. EHDRW: Efficacy of DRV/r in the randomised, controlled, Phase III ARTEMIS trial in treatment-naive, HIV-1-infected patients is independent of HIV-1 subtype (04/07/08)
     
  66. ALT Predicts Mortality & General Health - (04/04/08)
     
  67. Liver transplantation in HIV/HCV co-infected patients remains difficult: strategies to get these patients to earlier transplantation are needed - (04/04/08)
     
  68. Bone Disease in HIV: study finds, heavily pre-treated patients had Vitamin D deficiency & serum marker abnormalities & perhaps serum markers may be better for assessing patient risk than total BMD by DEXA - (04/03/08)
     
  69. EHDRW: One in 10 Genotyped Britons Started Therapy With Resistant HIV - Written by Mark Mascolini - (04/02/08)
     
  70. EHDRW: Resistance Measured by Clinical Cutoff Drops Sharply From 1998 to 2007 - Written by Mark Mascolini - (04/02/08)
     
  71. EHDRW: Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2 (04/02/08)
     
  72. CROI: Metabolic Complications: A CROI 2008 Summary Written by David Alain Wohl, MD - The University of North Carolina - (04/03/08)
     
  73. Mitochondrial Toxicity and HCV Liver Disease Progression in Coinfection - (04/02/08)
     
  74. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration - (04/02/08)
     
  75. Risk of myocardial infarction and nucleoside analogues Comment - (04/02/08)
     
  76. Abacavir and the potential risk of myocardial infarction Correspondence - (04/02/08)
     
  77. EHDRW: Prevalence of Darunavir-Linked Mutations Stays Low After Licensing - Written by Mark Mascolini - (03/31/08)
     
  78. EHDRW: Update on the prevalence of the 2007 darunavir resistance-associated mutations in samples received for routine clinical resistance testing - (03/31/08)
     
  79. EHDRW: Has Pretreatment Genotyping Improved Therapy? Answers From Germany - Written by Mark Mascolini - (03/31/08)
     
  80. EHDRW: Combined protease inhibitor (PI) and NNRTI resistance analysis of the pooled DUET trial: towards a regimen-based resistance interpretation (03/31/08)
     
  81. EHDRW: Virco Proposes Preliminary Biological Cutoffs for Integrase Inhibitors - Written by Mark Mascolini - (03/31/08)
     
  82. EHDRW: More Major Mutations in Newly Diagnosed, Untreated Italian Patients - Written by Mark Mascolini - (03/31/08)
     
  83. Early Communication about an Ongoing Safety Review of Ziagen (Abacavir) and Videx (Didanosine) from the FDA, March 27, 2008 - (03/28/08)
     
  84. Osteoporosis and Fractures Missing the Bridge? Commentary - (03/28/08)
     
  85. EHDRW: Nevirapine and Slow Genotyping Raise Risk of Resistance to Etravirine - Written by Mark Mascolini - (03/28/08)
     
  86. EHDRW: People With Subtype A or C May Respond More Rapidly to HAART - Written by Mark Mascolini - (03/28/08)
     
  87. EHDRW: "Historic" Resistance Profile Helps Predict PI and Overall Salvage Failure - Written by Mark Mascolini - (03/28/08)
     
  88. EHDRW: Single Mutations at Raltegravir Failure Suggest Low Resistance Barrier - Written by Mark Mascolini - (03/28/08)
     
  89. EHDRW: Background Drugs and Bad Adherence Explain Most Maraviroc Failures - Written by Mark Mascolini - (03/28/08)
     
  90. EHDRW: Trofile Assay Usually Matches Cell Test in Figuring Coreceptor Use - Written by Mark Mascolini - (03/28/08)
     
  91. EHDRW: "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)
     
  92. EHDRW: Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)
     
  93. EHDRW: "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)
     
  94. EHDRW: Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)
     
  95. EHDRW: Transmitted AZT/d4T-Resistant Virus Persists Up 4 Years Without Treatment - Written by Mark Mascolini - (03/27/08)
     
  96. EHDRW: Tibotec Refines List of Darunavir-Specific Mutations - Written by Mark Mascolini - (03/27/08)
     
  97. EHDRW: Classic Nonnucleoside Mutations Emerge Upon Etravirine Failure - Written by Mark Mascolini - (03/27/08)
     
  98. EHDRW: Up to Four 'Combined' Darunavir/Etravirine Mutations Needed for Sub-50-Copy Response. New Concept in Resistance: Combined Resistance to Multiple Drugs in Regimen - Written by Mark Mascolini - (03/27/08)
     
  99. Clinical Inertia in the Management of Low-Density Lipoprotein Abnormalities in an HIV Clinic - (03/26/08)
     
  100. Steatohepatitis (fatty liver): Risk factors and impact on disease severity in HIV/hepatitis C virus coinfection - (03/26/08)
     
  101. Pregnancy May Not Protect Against HIV Disease Progression - (03/25/08)
     
  102. Association of antiretroviral therapy with fibrinogen levels in HIV-infection - (03/25/08)
     
  103. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients - (03/25/08)
     
  104. TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals - (03/25/08)
     
  105. d4T/3TC/Nevirapine Fixed Dose Generic Approved by FDA - (03/25/08)
     
  106. Merck AIDS Vaccine Failure May Doom Promising Study - (03/25/08)
     
  107. CROI: Bone Disease Is Increased in HIV; Cancer Risk Increases with Age & Immune Deficiency - (03/25/08)
     
  108. CROI: Review of Bone Posters at CROI 2008 - Written by Turner Overton, M.D. - (03/24/08)
     
  109. CROI: HIV and Aging at CROI 2008 - (03/24/08)
     
  110. Randomized Trial of Once-Weekly PTH(1-84) on Bone Mineral Density and Remodeling - (03/20/08)
     
  111. HIV and hepatitis B co-infection in Africa Reflection and Reaction - (03/20/08)
     
  112. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa Review - (03/20/08)
     
  113. CROI: Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)
     
  114. Effects of Alendronate on BMD and Fracture Risk: The FOSIT Study - (03/17/08)
     
  115. Osteopenia: intervention & therapy - (03/17/08)
     
  116. Ten Years' Experience with Alendronate (5, 10 and 20 mg daily) for Osteoporosis in Postmenopausal Women - (03/17/08)
     
  117. HIV Proteins Accelerate Liver Disease; HIV Increases HCV Replication in a TGF-ß1-Dependent Manner - (03/14/08)
     
  118. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy - (03/14/08)
     
  119. CROI: Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08)
     
  120. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws - (03/14/08)
     
  121. Smoking Increases Bone Loss and Decreases Intestinal Calcium Absorption - (03/14/08)
     
  122. Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis - (03/14/08)
     
  123. 10 vs 5 Years of Bisphosphonate Treatment for Postmenopausal Osteoporosis EDITORIAL - (03/14/08)
     
  124. The attainment of peak bone mass: what is the relationship between muscle growth and bone growth? - (03/13/08)
     
  125. Osteoporosis and chronic kidney disease - (03/13/08)
     
  126. Benefit of Low-Fat Over Low-Carbohydrate Diet on Endothelial Health in Obesity - (03/13/08)
     
  127. FDA Issues New Prezista (Darunavir) Label Changes - (03/13/08)
     
  128. Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center - (03/13/08)
     
  129. CROI: Risk for Cardiovascular Disease and Regional Adipose Tissue Depots Among HIV-infected Men and Women in the Study of Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) (03/12/08)
     
  130. CROI: Inflammatory Markers Correlate with Carotid Intima-Media Thickness and Endothelial Activation in HIV-infected Patients (03/12/08)
     
  131. CROI: HIV and the Brain: Report from the 15th Conference on Retroviruses and Opportunistic Infections. - Written by Scott Letendre, J. Allen McCutchan, and Ronald J. Ellis (03/10/08)
     
  132. Bone disorders in chronic liver disease - (03/10/08)
     
  133. Medicare Spending to Surge; Chronic Diseases Increase; Hospitals Express Fear - (03/10/08)
     
  134. Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment: DAD Study - (03/10/08)
     
  135. CROI: Influence of NRTI Choice and Efavirenz Versus Lopinavir Treatment Options on Lipoatrophy-Associated Adipose Tissue Toxicity: A Longitudinal Study - (03/07/08)
     
  136. CROI: Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08)
     
  137. CROI: MELD is the Best Predictor of Pre-transplant Mortality in HIV-infected Liver Transplant Candidates???? NO - (03/07/08)
     
  138. It's More Than a Health Crisis: Economics Fuels HIV/AIDS for Black Americans; what drives the AIDS epidemic? - (03/07/08)
     
  139. CROI: Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08)
     
  140. CROI: Diastolic Dysfunction is Common in Asymptomatic HIV Patients - (03/07/08)
     
  141. CROI: Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (03/07/08)
     
  142. CROI: Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis - (03/07/08)
     
  143. CROI: The Effect of Hepatitis C Infection on Metabolic Parameters following Initial Therapy of HIV Infected Subjects with Nucleoside +/- NNRTI Regimens - (03/07/08)
     
  144. CROI: PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (03/07/08)
     
  145. Hemochromatosis Gene Polymorphisms, Mitochondrial Haplogroups, and Peripheral Lipoatrophy during ART - (03/05/08)
     
  146. Low Testosterone Levels are Common and Associated with Insulin Resistance in Men with Diabetes - (03/05/08)
     
  147. Efavirenz Potent Activity Across all CD4 & Viral Load Levels in Treatment-Naives - (03/05/08)
     
  148. Nevirapine (HSR) Hypersenstivity Reaction Safety & CD4 & Viral Load - (03/05/08)
     
  149. CROI: Endothelial Activation Markers Are Linked to HIV Status and Are Independent of ART and Lipoatrophy - (03/05/08)
     
  150. CROI: Prevalence and Risk Factors in HIV-infected Persons for Echocardiographic Abnormalities in the Era of Modern HAART - (03/05/08)
     
  151. HIV-Associated Lipoatrophy: Letting the Genome Out of the Bottle (Genetic Predisposition & Chronic Inflammation) EDITORIAL COMMENTARY - (03/05/08)
     
  152. US healthcare spending: the next ten years (expected to double) - (03/04/08)
     
  153. Name-based HIV reporting doesn't deter testing - (03/04/08)
     
  154. CROI: HIV-Specific Risk Factors for Nonalcoholic Fatty Liver Still Elusive - Written by Mark Mascolini (03/04/08)
     
  155. Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV-1-Infected Patients - (03/03/08)
     
  156. Human Papillomavirus (HPV) Genotype 84 Infection of the Male Genitalia: Further Evidence for HPV Tissue Tropism? CORRESPONDENCE - (03/03/08)
     
  157. GlaxoSmithKline Comments on Epzicom Data Concerning Epzicom from ACTG Study - (03/03/08)
     
  158. Long-Term Survival and Serious Cardiovascular Events in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy in VA [Brief Report: Clinical Science] - (03/03/08)
     
  159. The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract - (03/03/08)
     
  160. Effects of HIV & antiretroviral therapy on semen quality - (03/03/08)
     
  161. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study - (03/03/08)
     
  162. Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men - (03/03/08)
     
  163. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom - (03/03/08)
     
  164. New Approach Stops HIV At Earliest Stage Of Infection - (02/28/08)
     
  165. NIAID Modifies HIV Antiretroviral Treatment Study Combination Therapy that Includes ABC/3TC Found Less Effective in Subgroup of Antiretroviral-Naive Individuals - (02/28/08)
     
  166. CROI: Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08)
     
  167. Tests of new Tenofovir gel show promise for microbicide for women: phase II study reports safe. Tolerable, acceptable, adherence - (02/27/08)
     
  168. Short-Term Exercise Improves ß-cell Function and Insulin Resistance in Older People with Impaired Glucose Tolerance - (02/27/08)
     
  169. CROI: Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir - (02/27/08)
     
  170. CROI: GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Peripheral Glucose Disposal in a Healthy Rodent Model System - (02/27/08)
     
  171. CROI: Inefficient Renal Transport of Nucleotide Reverse Transcriptase Inhibitor GS-9148 Indicates Its Low Potential for Nephrotoxicity - (02/27/08)
     
  172. CROI: EVOLUTION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN HIV-INFECTED PATIENTS: INCIDENCE, CHARACTERISTICS AND PREDICTORS - (02/27/08)
     
  173. CROI: 48-Week Raltegravir Data Confirm Salvage Potency Across Pretreatment Variables - Written by Mark Mascolini - (02/27/08)
     
  174. CROI: Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy - (02/27/08)
     
  175. CROI: Efficacy and Safety of Double-Boosted Saquinavir (SQV)/Lopinavir/Ritonavir (LPV/r) in Nucleoside Pretreated Children at 96 Weeks - (02/26/08)
     
  176. CROI: Darunavir EvaLuation in Pediatric HIV-1-Infected treatment-experienced patients, DELPHI (Trial TMC114-C212) - (02/26/08)
     
  177. CROI: Effects of Diet and Exercise and/or Rosiglitazone on Body Composition and Lipids including Oxidized LDL in HIV+ and HIV- Men and Women - (02/26/08)
     
  178. CROI: Do Lipid Signals Favor Maraviroc Over Efavirenz in Untreated People? - Written by Mark Mascolini - (02/26/08)
     
  179. CROI: New NRTI Apricitabine Versus 3TC in 3TC-Experienced Patients: 24-Week Results - Written by Mark - (02/26/08)
     
  180. CROI: Failure and Resistance Differences Between Darunavir and Lopinavir in TITAN - Written by Mark - (02/26/08)
     
  181. CROI: Pharmacokinetics and Potent Anti-HIV-1 Activity of Amdoxovir Plus Zidovudine in a Randomized Double-blind Placebo-controlled Study - (02/26/08)
     
  182. CROI: New Nucleoside, Amdoxovir (DAPD), Potent When Combined With AZT Written by Mark Mascolini - (02/26/08)
     
  183. CROI: Sustained Treatment With Tesamorelin Needed to Keep Belly Fat Off - Written By Mark Mascolini - (02/26/08)
     
  184. CROI: Limb Fat Loss Must Reach 30% Before Patients and Physicians See It - Written By Mark Mascolini - (02/26/08)
     
  185. CROI: Insufficient Virus Suppression during HAART Is a Strong Predictor for the Development of AIDS-related Lymphoma: German CLINSURV Cohort - (02/25/08)
     
  186. CROI: Immunodeficiency and Risk of AIDS-defining and Non-AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006 - (02/25/08)
     
  187. CROI: Dose Escalation, Safety, Tolerability and Pharmacokinetics of a Novel HIV-1 NNRTI, IDX899 in Healthy Subjects - (02/25/08)
     
  188. CROI: Genotypic Resistance and Phenotypic Cross-Resistance Profile in vitro for a Novel NNRTI: IDX899 - (02/25/08)
     
  189. CROI: Therapeutic Drug Monitoring of Lopinavir and Saquinavir in Thai HIV-infected Children - (02/25/08)
     
  190. CROI: New and emerging antiretrovirals, Comparative ART Trials, and when to begin HAART after an OI- now or later - written by David Margolis, MD (02/25/08)
     
  191. Intensive glucose lowering arm of diabetes trial is stopped after excess deaths: ADVANCE study suggests different results - (02/22/08)
     
  192. Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men - (02/22/08)
     
  193. CROI: PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (02/22/08)
     
  194. CROI: Risk Factors for Reduced Bone Mineral Density In HIV-Infected Individuals In The Modern HAART Era - (02/22/08)
     
  195. CROI: On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08)
     
  196. CROI: Incidence Anal Squamous Intraepithelial Lesions (SIL) and Predictors of in the SUN Study after One Year of Follow-up - (02/22/08)
     
  197. CROI: Data on 52-Week Safety and Efficacy of Tesamorelin, a Growth Hormone-releasing Factor Analogue, in HIV-infected Patients with Abdominal Fat Accumulation - (02/22/08)
     
  198. The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy in SMART on Quality of Life - (02/21/08)
     
  199. Abbott Receives FDA Approval for SIMCOR (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management - (02/20/08)
     
  200. CROI: Bone Metabolism in HIV: CROI 2008 Update - written by Todd T. Brown, MD, PhD - (02/21/08)
     
  201. CROI: Steady State Pharmacokinetics and Safety of Atazanavir (ATV) After Treatment with ATV 300 mg/Ritonavir 100 mg (ATV/r) QD + ZDV/3TC During the 3rd Trimester of Pregnancy in HIV+ Women - (02/20/08)
     
  202. CROI: Multicenter, Retrospective Study of Incidence and Predictors of Adverse Events Associated With Nevirapine Use in a Cohort of Pregnant and Nonpregnant Women Treated at 3 Urban HIV Clinics in the United States - (02/20/08)
     
  203. CROI: Risk Factors for for Kidney Disease in EuroSida: Climbing CD4 Count Cuts Risk of Worsening Kidney Function - Written by Mark Mascolini (02/20/08)
     
  204. CROI: Racial Disparity in Kidney Disease At Hopkins: Sharp Racial Disparities in Kidney Trouble and End-Stage Disease in HIV+ Cohort - Written by Mark Mascolini - (02/20/08)
     
  205. CROI: Clinical Pharmacology at CROI 2008: Drug Delivery and Disposition, Drug Interactions, Pharmacogenetics and Applications to Patient Care - written by Courtney V. Fletcher, Pharm.D.(02/20/08)
     
  206. CROI: Co-Receptor Tropism, ENV Genotype, and in vitro Susceptibility to CCR5 Antagonists During Monotherapy Study with INCB9471 - (02/20/08)
     
  207. CROI: An Enhanced Version of the Trofile HIV Co-receptor Tropsim Assay Predicts Emergence of CXCR4 Use in ACTG5211 Vicriviroc Trial Samples - (02/19/08)
     
  208. CROI: Detection of Viral Co-receptor Tropism Changes with a High Sensitivity Phenotypic Assay among HIV-infected Patients with Drug-resistant Viremia - (02/19/08)
     
  209. CROI: Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings - (02/19/08)
     
  210. CROI: Switching from Combivir [CBV] (AZT/3TC) to Truvada [TVD] (TDF/FTC) Preserves Limb Fat: Results of a DEXA Sub-Study of a 48 Week Randomised Study - (02/19/08)
     
  211. CROI: Lower Noninfectious Disease Rates With HAART in All CD4 Brackets - Written by Mark Mascolini (02/19/08)
     
  212. CROI: Fat Changes Boost Heart Disease and Diabetes Risk in HIV-Infected Men - Written by Mark Mascolini (02/19/08)
     
  213. CROI: HIV & ART Led to Bone Loss (02/19/08)
     
  214. CROI: Worse HIV Control--Not Antiretrovirals--Linked to Low Bone Density in Vancouver; ART risk factor in 2nd study - Written by Mark Mascolini (02/19/08)
     
  215. Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy - (02/15/08)
     
  216. Immunity Not Mormalized Despite HAART: Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease - (02/15/08)
     
  217. HIV Persists in the Gut Despite Long-Term HIV Therapy - (02/15/08)
     
  218. Blood and Guts and HIV: Preferential HIV Persistence in GI Mucosa EDITORIAL COMMENTARY - (02/15/08)
     
  219. Major international diabetes study does not confirm increased risk of death reported by US trial - (02/15/08)
     
  220. HLA-B*5701 Screening for Hypersensitivity to Abacavir - (02/14/08)
     
  221. Risks in "improving" control of blood glucose - (02/14/08)
     
  222. Diabetes Study Partially Halted After Deaths - (02/14/08)
     
  223. CROI: Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/14/08)
     
  224. CROI: Liver Fibrosis in an Outbreak of Acute HCV in HIV-infected MSM; accelerated HCV progression if HIV is contracted before HCV (02/14/08)
     
  225. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces Liver-related Complications and Mortality in HIV/HCV-co-infected Patients by 9-Fold (02/14/08)
     
  226. CROI: CCR5 Antagonists, Tropism Assays: Entry and Entry Inhibitors at 15th Conference on Retroviruses and Opportunistic Infections 2008 -Written by Eric S. Daar, M.D. (02/14/08)
     
  227. CROI: Kidney - Proteinuria, Glomerular Filtration Rate Reductions, and Associated Factors among HIV-Infected and Uninfected Men in the Multicenter AIDS Cohort Study (MACS) (02/14/08)
     
  228. CROI: Clinical Associations of Extremity Fat Loss from ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Antiretroviral Therapy (ART) of Naive, HIV-1 infected Subjects (02/14/08)
     
  229. CROI: Kaletra Tablets Once vs Twice Daily - Written by Mark Mascolini (02/14/08)
     
  230. CROI: Etravirine With Darunavir Stays Strong Through 48 Weeks in DUET Trials - Written by Mark Mascolini (02/14/08)
     
  231. CROI: Metabolic Syndrome Does Not Up Death Risk in HIV Cohort--But Bad Lipids Do - Written by Mark Mascolini (02/14/08)
     
  232. CROI: SLAM-C Study: Maintenance Therapy in Coinfected (02/12/08)
     
  233. CROI: HLA-B*5701 Screening for Hypersensitivity to Abacavir (02/12/08)
     
  234. CROI: Renal Report by Wyatt/Klotman Mt Sinai (02/12/08)
     
  235. CROI: Multistudy Analysis Shows Enhanced CD4 Gain With CCR5 Antagonists - Written by Mark Mascolini (02/12/08)
     
  236. CROI: Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/12/08)
     
  237. CROI: Immediate Antiretrovirals During Acute OI Lower Death Risk: ACTG A5164 - Written by Mark Mascolini (02/12/08)
     
  238. CROI: Cardiovascular Risk Markers Greatly Inflate Death Risk in People With HIV; interruptions increase risk - Written by Mark Mascolini (02/12/08)
     
  239. CROI: Still Hard to Prove Therapeutic Benefit With Therapeutic Drug Monitoring - Written by Mark Mascolini (02/12/08)
     
  240. CROI: Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/12/08)
     
  241. CROI: Even at Counts Over 350, More CD4s Lower Death Risk in Untreated HIV+ People (02/12/08)
     
  242. CROI: Resistance After First Failure Looms as Larger Problem in Poor vs Rich Countries (02/12/08)
     
  243. CROI: Faster Death May Be the Price Paid for Delayed Switching After Failure (02/12/08)
     
  244. CROI: Abacavir (But Not Efavirenz) Weaker in Cohort Study Than in Clinical Trial (02/12/08)
     
  245. CROI: Maraviroc 48-Weeks Safety, Efficacy in Treatment-Experienced MOTIVATE 1 and 2 Study Pooled Analysis (02/12/08)
     
  246. CROI: Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/08/08)
     
  247. CROI: A phase I study to explore the activity and safety of SCH 532706, a small molecule chemokine receptor-5 (CCR5) antagonist in HIV-1 infected subjects (02/08/08)
     
  248. CROI: Tenofovir Bolsters Response to IFN/RBV in People With HCV/HIV - Written by Mark Mascolini (02/07/08)
     
  249. CROI: Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates (02/07/08)
     
  250. CROI: DUET-1:Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients (02/07/08)
     
  251. CROI: Characterization of virologic failures on darunavir/ritonavir in the randomized, controlled, Phase III TITAN trial in treatment-experienced patients (02/07/08)
     
  252. CROI: This is a BMS press release CASTLE STUDY SHOWED SIMILAR EFFICACY BETWEEN ONCE-DAILY REYATAZ (atazanavir sulfate)/RITONAVIR AND TWICE-DAILY LOPINAVIR/RITONAVIR AT 48 WEEKS IN PREVIOUSLY UNTREATED HIV-INFECTED ADULT PATIENTS (02/07/08)
     
  253. CROI: New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy - Tibotec press release at end of title (02/07/08)
     
  254. CROI: VICRIVIROC DEMONSTRATES POTENT AND SUSTAINED VIRAL SUPPRESSION THROUGH 48 WEEKS OF THERAPY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS (02/07/08)
     
  255. CROI: Vicriviroc in Combination Therapy With an Optimized Antiretroviral Regimen for Treatment-Experienced Subjects: The VICTOR-E1 Trial (02/07/08)
     
  256. CROI: The Effect of Vicriviroc Upon Viral Load in HIV/HCV Co-infected Patients Receiving a Ritonavir-containing Protease Inhibitor Regimen (02/07/08)
     
  257. CROI: Pharmacokinetics and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2 (02/07/08)
     
  258. CROI: Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (02/07/08)
     
  259. CROI: Once-Daily Darunavir Troughs Stay in Active Range for All ARTEMIS Patients - Written by Mark Mascolini (02/12/08)
     
  260. CROI: Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive (02/07/08)
     
  261. CROI: Tropism Change from Screening to Baseline Matters: Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-Naive Patients - Written by Mark Mascolini (02/06/08)
     
  262. CROI: Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/06/08)
     
  263. CROI: "No Treatment Options" No Longer a Growing Problem in Switzerland - Written by Mark Mascolini (02/06/08)
     
  264. CROI: Firstline Nukes Evaluated: What Makes a First Regimen Work? Answers From 79 Trials and Cohorts - Written by Mark Mascolini (02/06/08)
     
  265. CROI: Even Totally Controlled HIV Linked to Atherosclerosis Risk - Written by Mark Mascolini (02/06/08)
     
  266. CROI: "Elite Controller" Study Suggests No "Harmless" Level of HIV, Lose CD4s Faster - Written by Mark Mascolini (02/06/08)
     
  267. CROI: 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08)
     
  268. CROI: 48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08)
     
  269. CROI: Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naive (ARV) HIV-1 Infected Subjects (02/06/08)
     
  270. CROI: Boosted Atazanavir Noninferior to Lopinavir in Previously Untreated People - Written by Mark Mascolini (02/05/08)
     
  271. CROI: Abacavir & MI (myocardial infarction) Risk in D.A.D Study - Written by Mark Mascolini (02/05/08)
     
  272. CROI: What Explains Maraviroc Failures in the MERIT Trial of Naive Patients? - Written by Mark Mascolini (02/05/08)
     
  273. CROI: Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study - (02/05/08)
     
  274. CROI: Abacavir/3TC vs TDF/FTC: The HEAT Study - Written by Mark Mascolini (02/05/08)
     
  275. CROI: Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/05/08)
     
  276. CROI: Efficacy and Safety of Boosted Once-Daily Atazanavir and Twice-Daily Lopinavir Regimens in Treatment-Naive HIV-1 Infected Subjects CASTLE: 48-Week Results (02/05/08)
     
  277. CROI: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz in Combination with Zidovudine and Lamivudine (Combivir) for 48 Weeks to Treatment-naive HIV-infected Patients (02/05/08)
     
  278. CROI: Longer ART Drug Regimen Found to Help Babies Avoid HIV From Breastfeeding in Africa (02/05/08)
     
  279. CROI: Resuming Therapy Can't Reverse Progression Risk With Off-and-On Therapy - Written by Mark Mascolini (01/04/08)
     
  280. ORAL CANCER IN MEN CAUSED BY HPV VIRUS - (02/04/08)
     
  281. CROI: Circumcision Cuts HSV-2 Risk in Ugandan Men and STDs in Their Wives - Written by Mark Mascolini (01/04/08)
     
  282. CROI: Two Schering CCR5 Antagonists Get Spotlight at HIV Conference - Written by Mark Mascolini (01/04/08)
     
  283. CROI: Male Circumcision Challenges in African Study (01/04/08)
     
  284. CROI: Microbicide Protein Identified (01/04/08)
     
  285. CROI: Two New CCR5 Inhibitors, Actually 3 (01/04/08)
     
  286. CROI: Circumcising Men Slows Herpes Spread by 25%, May Reduce HIV Risk (01/04/08)
     
  287. Does Boosted PI Monotherapy Have Future Utility? Kaletra Monotherapy Studies: the OK Study and MONARK Study - (01/30/08)
     
  288. Insulin Resistance Prevents Response to Peinterferon in Coinfection, study reports - (01/29/08)
     
  289. Episodic HAART in SMART Study Has Worse Quality of Life - (01/29/08)
     
  290. When to Start HAART: CD4 <350 & Viral Load >100,000 Increase Risk for AIDS & Death - (01/29/08)
     
  291. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily HAART Regimens in ART-Naive Patients - (01/28/08)
     
  292. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 - (01/28/08)
     
  293. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen - (01/28/08)
     
  294. VAT (belly fat) is Increased in HIV+ Men, New Study Reports - Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities - (01/28/08)
     
  295. Influence of Cannabis Use on Severity of Hepatitis C Disease - (01/25/08)
     
  296. New Bone Therapy Denosumab vs Fosamax - (01/25/08)
     
  297. Bone Loss 62% in HIV+ - (01/23/08)
     
  298. Factors Associated with Low Bone Mineral Density (BMD) in a Large Cohort of HIV-Infected U.S. Adults - Baseline Results from the SUN Study -CROI 2007 - (01/23/08)
     
  299. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial - (01/23/08)
     
  300. Cardiovascular risks of calcium supplements in women Editorials - (01/23/08)
     
  301. 80% Bone Abnormalities in France Aquitane Cohort, 27% Osteoporosis - (01/23/08)
     
  302. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? - (01/22/08)
     
  303. Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease - (01/22/08)
     
  304. Tenofovir/FTC Prevents Vaginal HIV Infection in Mice - (01/22/08)
     
  305. High Prevalence of Anal Human Papillomavirus (HPV) Infection and Anal Cancer Precursors among HIV-Infected Persons in the Absence of Anal Intercourse - (01/22/08)
     
  306. FDA Approves INtELENCE(tM) (etravirine) for HIV Combination therapy; - INtELENCE is the first NNRtI to show antiviral activity in patients with NNRtI-resistant virus - - (01/22/08)
     
  307. FDA Approves New HIV Drug After Priority Review Etravirine tablets used in combination with other antiretroviral agents - (01/22/08)
     
  308. Etravirine (TMC-125) FDA Package Insert in PDF Format - (01/22/08)
     
  309. Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus (MRSA) Clone USA300 in Men Who Have Sex with Men - (01/15/08)
     
  310. Low Serum Testosterone Caused Fractures, study found - (01/15/08)
     
  311. Statins for people with diabetes Comment - (01/14/08)
     
  312. Statins for all diabetics urged - (01/14/08)
     
  313. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis - (01/14/08)
     
  314. 273 New HIV Host Proteins Discovery Reported HIV Gets By With a Lot of Help From Human Host - (01/14/08)
     
  315. NASH may be trash: causes of NASH - (01/14/08)
     
  316. linolenic acid (PUFAs) & peripheral neuropathy - (01/14/08)
     
  317. Researchers Find Cell Protein That Nips HIV in the Bud: DC-SIGN EFFICIENTLY BLOCKS HIV VIRAL BUDDING - (01/14/08)
     
  318. Non-Hodgkin Lymphoma Rare After HAART - (01/11/08)
     
  319. The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves ß-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose - (01/09/08)
     
  320. FDA ALERT: Bisphosphonates Can Cause Severe Musculoskeletal Pain - (01/08/08)
     
  321. "Is there a" The coming problem of HIV-associated Alzheimer's disease??? - (01/08/08)
     
  322. AIDS Patients Face Downside of Living Longer, Need for more Research on Diseases Associated with Aging - (01/07/08)
     
  323. Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial - (01/04/08)
     
  324. Oral Bispohosphonates (Fosomax) Found To protect Against Osteonecrosis of Jaw in Osteoporosis - (01/04/08)
     
  325. Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children - (01/03/08)
     
  326. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs EDITORIAL COMMENTARY - (01/03/08)
     
  327. Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine BRIEF REPORT - (01/03/08)
     
  328. Tenofovir Nephrotoxicity: Focusing Research Questions and Putting Them into Clinical Context EDITORIAL COMMENTARY - (01/02/08)
     
  329. Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy - (01/02/08)
     
  330. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN - (12/28/07)
     
  331. Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir [Letters to the Editor] - (12/27/07)
     
  332. Infrared Coagulator Treatment of High-Grade Anal Dysplasia in HIV-Infected Individuals: An AIDS Malignancy Consortium Pilot Study - (12/27/07)
     
  333. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term HAART Reach Same Mortality Rates as the General Population - (12/27/07)
     
  334. Darunavir Full Approval & For Naives: Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration - (12/21/07)
     
  335. ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission - (12/21/07)
     
  336. Generic Efavirenz FDA Approved - (12/21/07)
     
  337. Monogram Trofile Assay Superior to Pathway SensiTrop Assay - (12/19/07)
     
  338. Monogram Statement 'Study Reaffirms Superiority of Trofile(TM) Assay' - (12/19/07)
     
  339. BMD in Older Women Predicts Vertebral Fractures; vertebral fractures reduced survival; a single measure of BMD predicted vertebral factures - (12/18/07)
     
  340. GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected - (12/18/07)
     
  341. EUROPEAN COMMISSION APPROVES ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), THE FIRST ONCE-DAILY SINGLE TABLET REGIMEN FOR VIROLOGICALLY SUPPRESSED ADULTS WITH HIV-1 INFECTION - (12/17/07)
     
  342. Predictive factors of vascular intima media thickness in HIV-positive subjects - (12/17/07)
     
  343. HIV and mitochondrial toxicity in children (& adults) - (12/17/07)
     
  344. EU to approve one-pill-a-day treatment for HIV patients - (12/17/07)
     
  345. Low Incidence of Drug Resistance after Virologic Failure in HIV-1 Infected Subjects Randomized to Remain on their Current Protease Inhibitor (PI) or Switched to a Fosamprenavir Regimen for 24 Weeks (ELECT Study) - (12/14/07)
     
  346. Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes - (12/12/07)
     
  347. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes - (12/12/07)
     
  348. Study: 2 thiazolidinediones diabetes drugs raise heart risks - (12/12/07)
     
  349. Active Smoking and the Risk of Type 2 Diabetes, Increased 44% Risk - (12/12/07)
     
  350. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted. - (12/12/07)
     
  351. Mortality and morbidity improved following early ART (>350 CD4) initiation in HIV-infected adults in West Africa - (12/12/07)
     
  352. HIV Entry 3rd Wrkshp: Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - Written by Mark Mascolini - (12/12/07)
     
  353. HIV Entry 3rd Wrkshp: Analysis of the Protease Inhibitor/Reverse Transcriptase Inhibitor/Fusion Inhibitor Resistance Pattern of Treatment-emergent CXCR4-using Virus from Six Patients in the MOTIVATE Studies Shows no Evidence of Different Drug Resistance Profiles Being Archived in the CCR5-tropic versus CXCR4-using Populations - (12/11/07)
     
  354. HIV Entry 3rd Wrkshp: A band of optimists considers the road towards a distant goal: eradication; Report from HIV Eradication Conference, 3rd Intl Workshop on HIV Persistence during Therapy, West Indies, St Maartin - written by David Margolis MD, University of North Carolina at Chapel Hill- (12/11/07)
     
  355. HIV Entry 3rd Wrkshp: Viruses Utilizing Both CCR5 and CXCR4 Are Found in 5-13% of Acute HIV-1 Infections - (12/11/07)
     
  356. HIV Entry 3rd Wrkshp: Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2 - (12/11/07)
     
  357. Higher Vitamin D Supplements Advised for Older Black Women - (12/11/07)
     
  358. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C - (12/11/07)
     
  359. A band of optimists considers the road towards a distant goal: eradication; Report from HIV Eradication Conference, 3rd Intl Workshop on HIV Persistence during Therapy, West Indies, St Maartin - (12/11/07)
     
  360. BMS/Gilead ATRIPLA Commercialization in Europe - (12/11/07)
     
  361. HIV Entry 3rd Wrkshp: Low Sensitivity of Gene-Based Tools in Predicting Coreceptor Use - Written by Mark Mascolini - (12/09/07)
     
  362. HIV Entry 3rd Wrkshp: Correlates of Coreceptor Tropism in Three Large Cohorts: Does lower CD4 predict tropism switch? - Written by Mark Mascolini - (12/09/07)
     
  363. HIV Entry 3rd Wrkshp: CXCR4-Using HIV Found in 8.5% During Early HIV Infection - Written by Mark Mascolini - (12/09/07)
     
  364. HIV Entry 3rd Wrkshp: New More Sensitive Monogram Tropism Assay; Tweaked Trofile Assay Stronger in Spotting Dual/Mixed-Tropic Virus - Written by Mark Mascolini - (12/09/07)
     
  365. HIV Entry 3rd Wrkshp: Maraviroc Failure With X4 Virus Does Not Spur New Resistance to Other ARVs - Written by Mark Mascolini - (12/09/07)
     
  366. HIV Entry 3rd Wrkshp: Enhancements to the Trofile HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations and Earlier Detection of CXCR4-using Viruses in Sequential Patient Samples - (12/09/07)
     
  367. HIV Entry 3rd Wrkshp: Background Drugs and Low Maraviroc Levels Explain Resistance in MOTIVATE - Written by Mark Mascolini - (12/09/07)
     
  368. HIV Entry 3rd Wrkshp: Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - Written by Mark Mascolini - (12/09/07)
     
  369. Risk of extensive virological failure to the three original ART drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study - (12/07/07)
     
  370. Screening for diabetes and prediabetes COMMENTARY - (12/07/07)
     
  371. Metabolic Effects of a Growth Hormone-Releasing Factor (GHRH) in Patients with HIV - (12/06/07)
     
  372. Manipulation of the Growth Hormone Axis in Patients with HIV Infection EDITORIAL - (12/06/07)
     
  373. Cardiorespiratory Fitness and Adiposity as Mortality Predictors in Older Adults: Cardio fitness predicts mortality better than BMI, fat - (12/06/07)
     
  374. CDC may raise its estimate of annual HIV cases by 50% - (12/04/07)
     
  375. Generic Tenofovir Approved by FDA - (12/04/07)
     
  376. Changes in the DHHS ART Treatment Guidelines for Adults & and Adolescents - (12/04/07)
     
  377. HIV drug resistance 'on the rise' in China - (12/04/07)
     
  378. GSK responds quickly to query Avandia link to osteoporosis - (12/04/07)
     
  379. BRISTOL-MYERS SQUIBB JOINS WITH NJ CHILDREN'S HOSPITAL IN LAUNCHING NEW CENTER FOR IMMUNE SYSTEM DISORDERS AND INFECTIOUS DISEASES INCLUDING HIV/AIDS - (11/30/07)
     
  380. Do HIV/HCV coinfected have worse neurocognitive function - (11/30/07)
     
  381. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 - (11/30/07)
     
  382. A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy - (11/30/07)
     
  383. Joint Statement from Drs. Elias Zerhouni, Jack Whitescarver, and Anthony Fauci of the National Institutes of Health on World AIDS Day NIH Announces 2007 World AIDS Day Award Recipients - (11/30/07)
     
  384. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer - (11/30/07)
     
  385. EACS: An Open, Randomized, Two-Period, Crossover Study in Two Cohorts to Investigate the Effect of Steady-State TMC125 (etravirine) and the Combination of TMC125/Darunavir/Ritonavir on the Steady-State Pharmacokinetics of Oral Maraviroc in Healthy Subjects - (11/29/06)
     
  386. losing the battle against heart disease, editorial comment - (11/28/07)
     
  387. Heart disease mortality increases for young women 35-44 and negative trend for young men too - (11/28/07)
     
  388. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer - (11/28/07)
     
  389. Low BMD Associated with Both Low & High Trauma Accidents Causing Fractures in HIV-Negatives - (11/28/07)
     
  390. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis - (11/28/07)
     
  391. Magic Johnson & Abbott Events in NYC 11/30: Aims to Reduce New HIV Infections Among African-Americans by 50% by 5 Years - (11/28/07)
     
  392. New more sensitive assay to detect drug-resistant HIV - (11/28/07)
     
  393. Baseline Metabolic Syndrome Predicts Diabetes, study finds - (11/28/07)
     
  394. African-Americans at Risk for Kidney Disease - (11/28/07)
     
  395. The Reemerging HIV/AIDS Epidemic in Men Who Have Sex With Men - (11/28/07)
     
  396. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients - (11/28/07)
     
  397. EACS: Low-Level HIV-1 Viral Load Monitoring in Cerebrospinal Fluid: Possible Correlation to Antiretroviral Drug Penetration - (11/27/06)
     
  398. EACS: TMC278, a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral (ARV)-naive patients: Week 48 primary analysis of study TMC278-C204 - (11/27/06)
     
  399. EACS: Lower lipid levels in antiretroviral (ARV)-naive patients receiving the investigational NNRTI TMC278 versus efavirenz (EFV) - (11/27/06)
     
  400. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV - (11/26/07)
     
  401. Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression - (11/26/07)
     
  402. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease Data from the PROactive Study (PROactive 08) - (11/26/07)
     
  403. Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women - (11/26/07)
     
  404. Long-Term Predictors of Insulin Resistance Role of lifestyle and metabolic factors in middle-aged men - (11/26/07)
     
  405. EACS: Tipranavir/r (TPV/r) maintains long term virological suppression - Three year follow-up of RESIST - (11/26/06)
     
  406. EACS: Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score - (11/26/06)
     
  407. EACS: Genotypic tipranavir scores as predictors of response - (11/26/06)
     
  408. EACS: Risk Factors for Kidney Complications - Written by Mark Mascolini - (11/20/06)
     
  409. Vitamin D Supplements Appear to Be Associated With Lower Mortality - (11/19/07)
     
  410. EACS: Hepatic profile of tipranavir in treatment experienced HIV-1 infected individuals - (11/19/06)
     
  411. EACS: Linear modeling to estimate the contribution of each drug component of the regimens of highly treatment-experienced patients in RESIST - (11/19/06)
     
  412. EACS: Patients who responded to tipranavir/r (500/200 mg BID) plus new enfuvirtide (ENF) at Week 16 of RESIST studies maintain superior virologic and immunologic outcomes through Week 96; effects of adding 1 new class to potent protease inhibitor in highly treatment-experienced patients - (11/19/06)
     
  413. Merck Integrase raltegravir drug gets positive nod from EU - (11/16/07)
     
  414. Merck HIV vaccine trial data - (11/15/07)
     
  415. Improved cognitive function as a consequence of hepatitis C virus treatment - (11/15/07)
     
  416. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra (lopinavir/ritonavir) Tablet for Pediatric HIV Patients - (11/15/07)
     
  417. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy - (11/15/07)
     
  418. FDA Adds Boxed Warning for Heart Attacks to Anti-Diabetes Drug Avandia - (11/15/07)
     
  419. Increase in STDs-CDC Reports Worrisome Trends - (11/15/07)
     
  420. High HIV Rates in MSM in South Florida
    1 in 11 gay white men in Broward County (Ft Lauderdale) has HIV
    1 in 22 gay, bisexual men in Florida has HIV, study says     - (11/15/07)
     
  421. Prevalence of Chronic Kidney Disease in the United States - (11/08/07)
     
  422. EACS: Predictors of New Darunavir Resistance Mutations Upon Darunavir Failure - Mark Mascolini - (11/08/06)
     
  423. End-Stage Renal Disease Prevalence Climbing as Baby Boomers Age (11/07/07)
     
  424. Monogram Obtains Coverage for Trofile(TM) Assay from California ADAP Program (11/07/07)
     
  425. Single-dose tenofovir and emtricitabine for reduction of viral resistance to NNRTIs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial (11/07/07)
     
  426. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine, Commentary (11/07/07)
     
  427. EACS: Co-Receptor Tropism Predictions Based on V3 Loop Sequence in Antiretroviral-Experienced Patients are Specific but Insensitive for the Detection of CXCR4-using Variants - (11/05/06)
     
  428. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics (11/05/07)
     
  429. EACS: Insulin Resistance Imperils Response to Interferon in People With HCV/HIV - (11/04/06)
     
  430. Viral Load Predicts CD4 Decline to <350, Takes 2.5 Yrs (11/02/07)
     
  431. Generic Oral d4T Approved (11/02/07)
     
  432. EACS: Spontaneous HCV Clearance With HIV Lower Than Previously Thought? - Written by Mark Mascolini - (11/1/06)
     
  433. EACS: Body Composition Changes in ARV-Naive Subjects Treated with Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 96-Week CT and DEXA Data - (10/31/06)
     
  434. GSK Launches Abacavir Genetic Testing Program: doctor survey, education and complimentary tests (10/31/07)
     
  435. AIDS virus invaded U.S. from Haiti: study (10/30/07)
     
  436. AIDS Entered USA From Haiti in 1969 HIV's Path Out Of Africa: Haiti, The US Then The World (10/30/07)
     
  437. HIV Among Black Women in USA & Colorado (10/30/07)
     
  438. EACS: Once-Daily Fosamprenavir (FPV) Boosted with Either 100mg or 200mg of Ritonavir (r) Along with Abacavir (ABC)/Lamivudine (3TC): 48 Week Safety and Efficacy Results from COL100758 - (10/30/06)
     
  439. EACS: Single agent lopinavir/ritonavir (LPV/r) is as effective at maintaining viral suppression as continuation of standard ART at 24 weeks in patients who already have HIV RNA <50 copies/mL - (10/30/06)
     
  440. EACS: Single Agent Therapy (SAT) with Lopinavir/ritonavir (LPV/r) Controls HIV-1 Viral Replication in the Female Genital Tract - (10/30/06)
     
  441. EACS: Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study - (10/30/06)
     
  442. FDA Approves Administration of LEXIVA with Lower Dose of "Boosting" Medication Ritonavir (10/29/07)
     
  443. EACS: High Death Risk With HIV, HCV, and Decompensated Cirrhosis - Written by Mark Mascolini - (10/29/06)
     
  444. EACS: Do HCV Genotype and Load Affect Mortality With HIV? - Written by Mark Mascolini - (10/29/06)
     
  445. EACS: Switch to Atripla from Undetectable HAART - (10/29/06)
     
  446. EACS: Continuation of BID Boosted PI vs Switch to Once-daily Boosted Atazanavir in Subjects with Truncal Adiposity - (10/29/06)
     
  447. EACS: Good News and Bad News on Survival With Neurologic AIDS - Written by Mark Mascolini - (10/29/06)
     
  448. EACS: After First Year of HAART in 1996, Mortality Stable With Advanced Disease - Written by Mark Mascolini - (10/29/06)
     
  449. EACS: An assessment of HIV-HCV co-infection management in Spain: The ABHACO survey; 61-69% OF HIV infected patients are co-infected with the HCV too - (10/29/06)
     
  450. EACS: Long-term (4 years) efficacy of Lopinavir/ritonavir monotherapy for maintenance of HIV suppression - (10/29/06)
     
  451. EACS: Boosted Versus Unboosted Atazanavir After Long-Term Lopinavir - Written by Mark Mascolini - (10/26/06)
     
  452. EACS: ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients - (10/29/06)
     
  453. EACS: ARTEMIS Study: Once-Daily Darunavir, Once-Daily Lopinavir, and Twice-Daily Lopinavir Compared - Written by Mark Mascolini - (10/26/06)
     
  454. EACS: Prognostic Factors of Virological Success in Antiretroviral-naive Patients Receiving LPV Monotherapy in the MONARK trial - (10/29/06)
     
  455. EACS: Lopinavir/ritonavir monotherapy versus lopinavir/ritonavir and two nucleosides for maintenance therapy of HIV. Ninety-six week results of a randomized, controlled, open-label clinical trial (OK04 Study) (10/26/06)
     
  456. EACS: Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine; ETR) in treatment-experienced HIV-1-infected patients (10/26/06)
     
  457. EACS: The Incidence of Severe Liver Enzyme Abnormalities and Hepatic Adverse Events in the Maraviroc Clinical Development Programme (10/26/06)
     
  458. EACS: Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials (10/26/06)
     
  459. EACS: Efficacy of Raltegravir, an HIV Integrase Inhibitor, in Combination with Regimens Containing Enfuvirtide, Darunavir, or Tipranavir in Patients with Triple-class Resistant Virus: Combined Results from BENCHMRK-1 and BENCHMRK-2 (10/26/06)
     
  460. EACS: Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) safety and tolerability in treatment-experienced, HIV-1-infected patients (10/26/06)
     
  461. Panacos Announces Greater than 1 Log10 Mean Reduction in 300 mg Bevirimat Cohort (10/25/07)
     
  462. EACS: Why Do British Docs Follow Antiretroviral Rules Less and Less? - Written by Mark Mascolini - (10/25/06)
     
  463. EACS: Saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients The Gemini Study (10/25/06)
     
  464. EACS: Long-Term Kidney Damage From Indinavir But Not Tenofovir - Written by Mark Mascolini - (10/25/06)
     
  465. EACS: Cocaine Boosts Cardiovascular Risk in Spanish Patients With HIV - Written by Mark Mascolini - (10/25/06)
     
  466. EACS: Lopinavir Monotherapy Fails More in People With Non-B Subtypes - Written by Mark Mascolini - (10/25/06)
     
  467. EACS: Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients (press release from Roche) - Written by Mark Mascolini - (10/25/06)
     
  468. EACS: Combined 24-Week Efficacy Data on the Integrase Inhibitor Raltegravir - Written by Mark Mascolini - (10/25/06)
     
  469. EACS: Efficacy and Safety of Maraviroc (MVC) Plus Optimized Background Therapy (OBT) In Viraemic, Antiretroviral Treatment-Experienced Patients Infected with CCR5-Tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-Week Results - (10/25/06)
     
  470. EACS: Two Tools for Sharpening Darunavir Response Predictions - Written by Mark Mascolini - - (10/17/06)
     
  471. EACS: Response to Nonnucleoside TMC278 Sustained Through 48 Weeks - Written by Mark Mascolini - - (10/17/06)
     
  472. EACS: Four Double-DUET Analyses Give Closer Look at New NNRTI - Written by Mark Mascolini - - (10/17/06)
     
  473. Abbott's FDC Simvastatin+Niaspan (10/24/07)
     
  474. Liver Fat in the Metabolic Syndrome (10/24/07)
     
  475. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network (10/24/07)
     
  476. Physical Activity and Reduced Risk of Cardiovascular Events Potential Mediating Mechanisms (10/24/07)
     
  477. Keeping quiet: microRNAs in HIV-1 latency; commentary by Siliciano and Han (10/22/07)
     
  478. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes (10/22/07)
     
  479. UCSF Anal Cancer Information Website: screening, treatment, and referral list of doctors in numerous cities (10/22/07)
     
  480. Hearing loss with erectile dysfunction drugs (10/22/07)
     
  481. Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid (10/22/07)
     
  482. HAART Drop-out rate of African AIDS patients causes concern (10/22/07)
     
  483. High Rates of HIV Among Black & Latino MSM (10/19/07)
     
  484. New Study: HIV+ Blacks Have High Rates of End-Stage Renal Disease in USA VA (10/19/07)
     
  485. European licence for Roche HIV drug Viracept re-established by European Commission (10/19/07)
     
  486. HEALTH CANADA APPROVES ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), THE FIRST ONCE-DAILY SINGLE TABLET REGIMEN FOR HIV (10/17/07)
     
  487. Thailand's FDA Registers Generic of Abbott's Aluvia Under Compulsory Licensing Program (10/17/07)
     
  488. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults (10/15/07)
     
  489. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores [Research Letters] (10/15/07)
     
  490. Fuzeon Sales Increased; Trimeris Reports Third Quarter 2007 FUZEON Sales Results (10/15/07)
     
  491. Maraviroc approved in Canada to treat HIV, first new class in 10 years (10/15/07)
     
  492. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART [Research Letters] (10/15/07)
     
  493. Merck Gets FDA Approval For New HIV Treatment Integrase Inhibitor Raltegravir (10/15/07)
     
  494. HIV/AIDS Among Hispanics --- United States, 2001--2005 (10/15/07)
     
  495. FDA Approves of Isentress (raltegravir) (10/15/07)
     
  496. FDA Approves ISENTRESS (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor (10/15/07)
     
  497. HIV's Striking Impact on HCV. HCV-HIV Coinfection: Simple Messages from a Complex Disease (10/15/07)
     
  498. Implementing Routine HIV Testing: The Role of State Law; CDC recommendation for routine testing is not being implemented, why? (10/15/07)
     
  499. Routine HIV screening becomes California law (10/15/07)
     
  500. Prevalence and factors associated with dry skin in HIV infection: the FRAM study (10/15/07)
     
  501. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN (10/11/07)
     
  502. Psychological Stress and Disease (HIV/AIDS) (10/11/07)
     
  503. Psychosis in a 12-Year-Old HIV-Positive Girl with an Increased Serum Concentration of Efavirenz (10/11/07)
     
  504. IDSA: Safety and tolerability of KP-1461 in phase 1, dose-ranging study in highly ART experienced HIV infected persons - (10/11/07)
     
  505. Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26 (10/10/07)
     
  506. Onions Reduce Pancreatic Cancer Risk: Flavonols and Pancreatic Cancer Risk (10/10/07)
     
  507. Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA (10/10/07)
     
  508. IDSA: 48-Week Safety and Efficacy of Maraviroc in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Patients Infected with Dual/Mixed-Tropic HIV-1 - (10/9/07)
     
  509. IDSA: Switching from Lopinavir/Ritonavir (LPV/r) Soft Gel Capsule (SGC) to Tablet Formulation improves Tolerability in Indigent AIDS Clinic - (10/9/07)
     
  510. IDSA: HIV & Aging: Overweight & Hypertension Increasing - (10/9/07)
     
  511. IDSA: TMC125 safety and tolerability: 24-week results of the pooled DUET-1 and -2 trials - (10/9/07)
     
  512. IDSA: Pooled 24-week results of DUET-1 and -2: efficacy of TMC125 in treatment-experienced HIV-1-infected patients - (10/9/07)
     
  513. IDSA: Influence of Baseline Factors on Virologic Response to Darunavir/Ritonavir (DRV/r) vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN - (10/9/07)
     
  514. Roche/Trimeris gives up on device to inject HIV drug (10/05/07)
     
  515. Trends in perimortal conditions and mortality rates among HIV-infected patients: HIV deaths decline 75%; Hepatitis deaths Up 4-Fold (10/05/07)
     
  516. ICAAC: Antiretroviral Therapy at 47th ICAAC 2007 (Sept 2007): RTV-boosted PIs in treatment-naives; CCR5 antagonists; integrase inhibitors - written by Eric S. Daar, M.D. - (10/02/07)
     
  517. ICAAC: In Vitro Antiviral Potency and Preclinical Pharmacokinetics of GSK364735 Predict Clinical Efficacy in a Phase 2a Study - (10/01/07)
     
  518. ICAAC: GSK364735 is a Potent Inhibitor of HIV Integrase and Viral Replication - (10/01/07)
     
  519. ICAAC: Resistance Mechanisms of the K70E HIV-1 Reverse Transcriptase Mutant to GS-9148 and Other NRTIs - (10/01/07)
     
  520. ICAAC: Novel 2'-Fluoro Substituted Nucleotide HIV Reverse Transcriptase Inhibitor GS-9148 Exhibits Low Potential for Mitochondrial Toxicity In Vitro - (10/01/07)
     
  521. ICAAC: Novel Nucleotide Inhibitor GS-9148 Selects for a K70E Mutation in HIV-1 Reverse Transcriptase and Low-Level Resistance In Vitro - (10/01/07)
     
  522. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events (09/28/07)
     
  523. 7 Pharma firms join forces to identify patients at risk of adverse events by developing genetic tests (09/28/07)
     
  524. Diabetes Care Very Hard for Patients: Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments (09/28/07)
     
  525. ICAAC: Interrupting antiretroviral therapy does not reduce CVD risk and activates the immune system - (09/28/07)
     
  526. ICAAC: Efficacy and Safety of Protease Inhibitor Replacemet for Nevirapine In Patients with High CD4 Lymphocyte Cell Counts: A Systematic Review - (09/28/07)
     
  527. ICAAC: Prediction of disease progression by HIV co-receptor tropism (CRT) in persons (P) with untreated chronic HIV infection - (09/27/07)
     
  528. ICAAC: Co-receptor Tropism Predictions Based on V3 Loop Sequence in Antiretroviral-Experienced Patients are Specific but Insensitive for the Detection of CXCR4-using Variants - (09/27/07)
     
  529. ICAAC: Enhancements to the Trofile™ HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations - (09/27/07)
     
  530. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine (09/26/07)
     
  531. Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck's Investigational HIV Vaccine Candidate (09/26/07)
     
  532. PFIZER'S CELSENTRI (Maraviroc) APPROVED IN THE EUROPEAN UNION, PROVIDING A NOVEL TREATMENT OPTION FOR TREATMENT-EXPERIENCED HIV PATIENTS (09/26/07)
     
  533. Chronic kidney disease in HIV infection: an urban epidemic [RESEARCH LETTERS] (09/26/07)
     
  534. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART [RESEARCH LETTERS] (09/26/07)
     
  535. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. [Correspondence] (09/26/07)
     
  536. Prevalence of Colorectal (cancer) Neoplasm Among Patients With Newly Diagnosed Coronary Artery Disease, and the Metabolic Syndrome (09/26/07)
     
  537. Safety of Statin Therapy in HIV/Hepatitis C Virus-Coinfected Patients [Letters to the Editor] (09/26/07)
     
  538. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study [Rapid Communication] (09/26/07)
     
  539. ICAAC: Abacavir-Containing HAART Reduces the Chances for Sustained Virological Response to Pegylated-Interferon pllus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C - (09/26/07)
     
  540. ICAAC: Antiviral Effects and Tolerability of the CCR5 Monoclonal antibody PRO 140: A Proof of Concept Study in HIV-Infected Individuals - (09/25/07)
     
  541. ICAAC: Cancer Rates Higher in HIV+, CD4s Lower - (09/25/07)
     
  542. ICAAC: Lopinavir (LPV) Cerebrospinal Fluid (CSF) Trough Concentrations in HIV-infected Adults - (09/25/07)
     
  543. ICAAC: Pharmacokinetics of TMC125 in HIV-negative volunteers with mild or moderate hepatic impairment - (09/25/07)
     
  544. ICAAC: Raltegravir (RAL) Dose Proportionality and Effect of Food - (09/24/07)
     
  545. ICAAC: Limb Fat Increased by 25% 3 Years After Switch to TDF from d4T - (09/24/07)
     
  546. ICAAC: Development of resistance in patients with virologic failure (VF) on darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r): results of a randomized, controlled, Phase III trial in treatment-experienced patients (TITAN) - (09/20/07)
     
  547. The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) (09/20/07)
     
  548. ICAAC: The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) - (09/19/07)
     
  549. ICAAC: Efficacy and Safety of Darunavir/ritonavir versus Lopinavir/ritonavir in ARV Treatment-Naive HIV-1-Infected Patients at Week 48: ARTEMIS (TMC114-C211) - (09/19/07)
     
  550. ICAAC: Efficacy and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With CCR5-Tropic HIV-1: 48-Week Results of MOTIVATE 1 - (09/19/07)
     
  551. ICAAC: Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials - (09/19/07)
     
  552. ICAAC: Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) versus placebo in treatment-experienced HIV-1-infected patients - (09/19/07)
     
  553. ICAAC: 48 Week Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus, Phase II Protocol 005 - (09/19/07)
     
  554. ICAAC: Studies Highlight Superior Performance of Trofile(TM) Assay - (09/19/07)
     
  555. ICAAC: Two-Year Follow-up of Treatment-Experienced Patients on Vicriviroc (VCV) - (09/19/07)
     
  556. ICAAC: New HIV Drugs, Final Oral Slide Session at ICAAC 2007 - (09/19/07)
     
  557. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir [Research Letters] (09/18/07)
     
  558. Urolithiasis (kidney stones) in HIV-Positive Patients Treated with Atazanavir (09/18/07)
     
  559. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients (09/18/07)
     
  560. Eltrombopag Phase III study to Initiate and Maintain Interferon Antiviral Treatment to Subjects With Hepatitis C Related Liver Disease (09/18/07)
     
  561. ICAAC: Fosamprenavir or Atazanavir Boosted with Ritonavir Given Once Daily with Tenofovir /Emtricitabine in Antiretroviral Naive HIV-Infected Patients: ALERT Study Virology Analysis Through 48 Weeks - (09/17/07)
     
  562. ICAAC: Clinical Presentation of Hypersensitivity Reaction to Abacavir (ABC HSR) by HLA-B*5701 Status - (09/17/07)
     
  563. ICAAC: Long-term Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) Versus Lopinavir/Ritonavir (LPV/r) over 96 Weeks - (09/17/07)
     
  564. Defining HIV Susceptibility to New Antiretroviral Agents-Darunavir EDITORIAL (09/14/07)
     
  565. DHHS Perinatal